{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:09:44Z","timestamp":1789193384082,"version":"build-2803163510"},"publisher-location":"Berlin, Heidelberg","reference-count":26,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/82_2026_355","type":"book-chapter","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:43:01Z","timestamp":1789191781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid Vaccine Development in Pre-pandemic Preparedness: Platform Analytics, Regulatory Readiness, and Digital Innovation"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-9061","authenticated-orcid":false,"given":"Anna","family":"S\u00e4rnef\u00e4lt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-8332","authenticated-orcid":false,"given":"Ingrid","family":"Kromann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"355_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-48408-7_16","volume-title":"Principles and practice of emergency research response","author":"A Aatresh","year":"2024","unstructured":"Aatresh A, Lurie N, Hatchett R (2024) 13 Accelerating vaccine development: The 100 Days Mission. In: Sorenson RA (ed) Principles and practice of emergency research response. Springer, Cham.https:\/\/doi.org\/10.1007\/978-3-031-48408-7_16"},{"key":"355_CR2","unstructured":"Anyadiegwu M, Hesselink R, Kromann I (2025) The need for manufacturing speed. Accelerating vaccine availability for emergency use against disease threats. PDA letter Available at: https:\/\/www.pda.org\/pda-letter-portal\/home\/full-article\/the-need-for-manufacturing-speed"},{"key":"355_CR24","unstructured":"Askary H, Guzzi A, Ali M, Rovira O (2026) 5.5.6 CMC Platform Best Practices. In Pandemic Preparedness & Response Playbook. The Global Health Network. Available at:https:\/\/tghncollections.pubpub.org\/pandemic-preparedness-response-playbook"},{"key":"355_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41541-023-00692-0","volume":"8","author":"MS Avumegah","year":"2023","unstructured":"Avumegah MS, Mattiuzzo G, S\u00e4rnef\u00e4lt A et al (2023) Availability and use of standards in vaccine development. NPJ Vaccines 8:95. https:\/\/doi.org\/10.1038\/s41541-023-00692-0","journal-title":"NPJ Vaccines"},{"key":"355_CR4","doi-asserted-by":"publisher","unstructured":"Bennett H, Embry A (2025) Commentary: Preparing for the 100 days mission: end-to-end transformation for emerging infectious disease preparedness. Vaccine Insights 4(9):341\u2013350.https:\/\/doi.org\/10.18609\/vac.2025.049","DOI":"10.18609\/vac.2025.049"},{"key":"355_CR5","unstructured":"European Medicines Agency (2015) Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products \u2013 report on actions taken. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/review-and-update-ema-guidelines-implement-best-practice-regard-3rs-replacement-reduction-and-refinement-regulatory-testing-medicinal-products-report-actions-taken_en.pdf"},{"key":"355_CR6","unstructured":"European Commission (2023) Proposal for a regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394\/2007 and Regulation (EU) No 536\/2014 and repealing Regulation (EC) No 726\/2004, Regulation (EC) No 141\/2000 and Regulation (EC) No 1901\/2006. COM\/2023\/193 final. Available at: https:\/\/health.ec.europa.eu\/publications\/proposal-regulation-laying-down-union-procedures-authorisation-and-supervision-medicinal-products_en"},{"key":"355_CR7","unstructured":"European Medicines Agency (2023) Guideline on real-time release testing (formerly guideline on parametric release). Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-real-time-release-testing-formerly-guideline-parametric-release-revision-1_en.pdf"},{"key":"355_CR8","unstructured":"FDA (2023) Advancing alternative methods at FDA. Available at: https:\/\/www.fda.gov\/science-research\/about-science-research-fda\/advancing-alternative-methods-fda"},{"key":"355_CR9","unstructured":"FDA (2025) Using artificial intelligence in pharmaceutical manufacturing. Available at: https:\/\/www.fda.gov\/media\/167973\/download"},{"key":"355_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12247-025-10272-5","volume":"21","author":"L Fitzgerald","year":"2026","unstructured":"Fitzgerald L, Niarchou E, Jones I et al (2026) Emerging digital innovations in pharmaceutical manufacturing quality: a systematised review. J Pharm Innov 21:46. https:\/\/doi.org\/10.1007\/s12247-025-10272-5","journal-title":"J Pharm Innov"},{"issue":"3","key":"355_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.vacune.2024.07.004","volume":"25","author":"IR Guzm\u00e1n-Cervantes","year":"2024","unstructured":"Guzm\u00e1n-Cervantes IR, Parra-Hern\u00e1ndez E, Svarch-P\u00e9rez AE, Z\u00fa\u00f1iga-Estrada A, Alcocer-Varela JC (2024) Importance of national regulatory agencies and national control laboratories in the face of the COVID-19 pandemic: experience of Federal Commission for the Protection against sanitary risks (COFEPRIS). Vacunas (English Edition) 25(3):424\u2013427. https:\/\/doi.org\/10.1016\/j.vacune.2024.07.004","journal-title":"Vacunas (English Edition)"},{"key":"355_CR12","unstructured":"International Council for Harmonisation (2005) ICH Q5E: comparability of biotechnological\/biological products subject to changes in their manufacturing process. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q5E%20Guideline.pdf"},{"issue":"11","key":"355_CR13","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/bit.26383","volume":"114","author":"M Jiang","year":"2017","unstructured":"Jiang M, Severson KA, Love JC, Madden H, Swann P, Zang L, Braatz RD (2017) Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing. Biotechnol Bioeng 114(11):2445\u20132456. https:\/\/doi.org\/10.1002\/bit.26383","journal-title":"Biotechnol Bioeng"},{"key":"355_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/vaccines13080849","volume":"13","author":"J Kim","year":"2025","unstructured":"Kim J, Sabet-Azad R, Patel D, Malin G, Askary SH, S\u00e4rnef\u00e4lt A (2025) Fast-tracking vaccine manufacturing: CEPI\u2019s rapid response framework for the 100 days mission. Vaccine 13:849. https:\/\/doi.org\/10.3390\/vaccines13080849","journal-title":"Vaccine"},{"key":"355_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41541-023-00617-x","volume":"8","author":"C Milne","year":"2023","unstructured":"Milne C, Wagner R, Cano F et al (2023) Independent control of COVID-19 vaccines by EU official control authority batch release: challenges, strengths and successes. NPJ Vaccines 8:22. https:\/\/doi.org\/10.1038\/s41541-023-00617-x","journal-title":"NPJ Vaccines"},{"key":"355_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-021-00368-7","volume":"6","author":"NJ Rose","year":"2021","unstructured":"Rose NJ, Stickings P, Schepelmann S et al (2021) National control laboratory independent lot testing of COVID-19 vaccines: the UK experience. NPJ Vaccines 6:100. https:\/\/doi.org\/10.1038\/s41541-021-00368-7","journal-title":"NPJ Vaccines"},{"key":"355_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/vaccines13080793","volume":"13","author":"R Sabet-Azad","year":"2025","unstructured":"Sabet-Azad R, Hoath C, B\u00e9zay N, S\u00e4rnef\u00e4lt A (2025) The platform readiness dashboard: a tool for evaluating vaccine platform suitability for a rapid response to epidemic and pandemic threats. Vaccine 13:793. https:\/\/doi.org\/10.3390\/vaccines13080793","journal-title":"Vaccine"},{"key":"355_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41541-021-00317-4","volume":"6","author":"G Sanyal","year":"2021","unstructured":"Sanyal G, S\u00e4rnef\u00e4lt A, Kumar A (2021) Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. NPJ Vaccines 6:53. https:\/\/doi.org\/10.1038\/s41541-021-00317-4","journal-title":"NPJ Vaccines"},{"issue":"1","key":"355_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18609\/vac.2022.001","volume":"1","author":"A S\u00e4rnef\u00e4lt","year":"2022","unstructured":"S\u00e4rnef\u00e4lt A, Kromann I (2022) Analytical development for rapid response vaccines: start early, think ahead. Vaccine Insights 1(1):1\u20133. https:\/\/doi.org\/10.18609\/vac.2022.001","journal-title":"Vaccine Insights"},{"key":"355_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2202669","volume":"387","author":"M Saville","year":"2022","unstructured":"Saville M, Cramer JP, Downham M, Hacker A, Lurie N, Van der Veken L, Whelan M, Hatchett R (2022) Delivering pandemic vaccines in 100 days \u2013 what will it take? N Engl J Med 387:e3. https:\/\/doi.org\/10.1056\/NEJMp2202669","journal-title":"N Engl J Med"},{"issue":"5","key":"355_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/pr9050748","volume":"9","author":"A Schmidt","year":"2021","unstructured":"Schmidt A, Helgers H, Vetter FL, Juckers A, Strube J (2021) Digital twin of mRNA-based SARS-COVID-19 vaccine manufacturing towards autonomous operation for improvements in speed, scale, robustness, flexibility and real-time release testing. Processes 9(5):748. https:\/\/doi.org\/10.3390\/pr9050748","journal-title":"Processes"},{"issue":"9","key":"355_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/vaccines12091000","volume":"12","author":"F Schnetzinger","year":"2024","unstructured":"Schnetzinger F, Cl\u00e9net D, Gilbert PA, Guzzi A, Paludi M, Weusten J, Hesselink R (2024) Stability preparedness: the not-so-cold case for innovations in vaccine stability modelling and product release. Vaccines (Basel) 12(9):1000. https:\/\/doi.org\/10.3390\/vaccines12091000","journal-title":"Vaccines (Basel)"},{"key":"355_CR23","unstructured":"SciY (2025) Webinar, implementing digital analytical methods: foundation for laboratory automation, frictionless tech transfer, and AI-driven innovation. Available at: https:\/\/www.sciy.com\/en\/news-and-events\/webinars\/2025\/implementing-digital-analytical-methods-foundation-for-laboratory-automation-frictionless-tech-transfer-and-ai-driven-innovation.html"},{"key":"355_CR25","unstructured":"WHO (2023) National control laboratories. Available at: https:\/\/extranet.who.int\/prequal\/vaccines\/national-control-laboratories"},{"key":"355_CR26","unstructured":"WHO (2025) Guidelines on the replacement or removal of animal tests for the quality control of biological products. Available at: https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/bs-documents-(ecbs)\/post-ecbs-documentation\/who-guidelines.replacement-or-removal-of-animal-tests.pdf?sfvrsn=fab3a0f8_7&download=true"}],"container-title":["Current Topics in Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2026_355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:43:06Z","timestamp":1789191786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2026_355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1007\/82_2026_355","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"13 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The author(s) has no competing interests to declare that are relevant to the content of this chapter.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declares that this chapter does not include primary research with human participants.The author(s) declares that this chapter does not include primary studies involving animals.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}